Supplemental table S2A: Putative tumor suppressor highly down regulated in medulloblastoma versus normal cerebellum datasets

Gene Atxn7l1 Gad1 Gucy1a3 Aqp4 Kcnd3 Grid2 Tcfap2b Cacnb2 Calb1 Camk2d Car8 Elmo1 Elovl7 Gdf10 Gja1 Map2k7 Neurod2 Sema4f Snrpn Syt1 Chchd7 Frmd5 Ednrb Cpeb2 Sema5a Als2 Slc8a1 Mtch2 Slc1a3 ZNF521 Zfhx4 Unc5c Limch1 Runx1t1 SPTBN1 Rad23a Pax3

Supplemental table S2B: Established(GO) tumor suppressor genes down regulated in medulloblastoma (MB) versus normal cerebellum datasets

Gene Reported tumor suppressor in a.o. Reported tumor suppressor in MB (Y/N) Cables1 Colorectal (1), Ovarian (2) N Cygb Lung and Breast (3) N Hopx Endometrial (4), Gastric (5) N Ptprj Colorectal (6), Meningioma(7) N Dab2ip Prostate (8), Breast (9), Lung (10) N Errfi1 Glioblastoma (11) N Fat2 Squamous Carcinoma (12) N Gas8 Breast (13) N Lrp1b Lung (14), Urothelial (15), Thyroid (16) N Lrrc3b Gastric (17), Colorectal (18) N Madd Ovarian (19) N Mal Lung (20), Colorectal (21), Breast (22) N Mapre3 HNSCC (23) N Ndrg4 Colorectal (24) N Opcml Ovarian(25), Glioma & Medulloblastoma (26) Y (26) Slc9a3r1 Liver (27), Breast (28) N Spint2 Renal (29), Gastric (30), Medulloblastoma (31) Y (31) Dlc1 Hepatocellular (32), Breast and Colon and Prostate (33), N Supratentorial Primitive Neuro -Ectoderrmal Tumor (34) Lsamp Osteosarcoma(35) N Sash1 Breast(36), Colorectal(37) N Id4 Colorectal (38), Leukemia(39), Breast (40), Prostate (41) N Fabp3 Breast(42) N Clca2 Breast (43), Colorectal (44) N Stat5b Hepatocellular(45) N Runx1 Leukemia (46) N Cdh1 Gastric&breast (47), Colorectal (48), Ovarian (49), Medulloblastoma Y (50) (50) Reference List

1. Kirley SD, D'Apuzzo M, Lauwers GY, Graeme-Cook F, Chung DC, Zukerberg LR. The Cables gene on 18Q regulates colon cancer progression in vivo. Cancer Biol Ther 2005;4:861-863.

2. Sakamoto H, Friel AM, Wood AW, Guo L, Ilic A, Seiden MV, et al. Mechanisms of Cables 1 gene inactivation in human ovarian cancer development. Cancer Biol Ther 2008;7:180-188.

3. Shivapurkar N, Stastny V, Okumura N, Girard L, Xie Y, Prinsen C, et al. Cytoglobin, the newest member of the globin family, functions as a . Cancer Res 2008;68:7448-7456.

4. Yamaguchi S, Asanoma K, Takao T, Kato K, Wake N. Homeobox gene HOPX is epigenetically silenced in human uterine endometrial cancer and suppresses estrogen-stimulated proliferation of cancer cells by inhibiting serum response factor. Int J Cancer 2009;124:2577-2588.

5. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Kokubo K, et al. Potential utility of HOP homeobox gene promoter methylation as a marker of tumor aggressiveness in gastric cancer. Oncogene 2010;29:3263-3275.

6. Venkatachalam R, Ligtenberg MJ, Hoogerbrugge N, Schackert HK, Gorgens H, Hahn MM, et al. Germline epigenetic silencing of the tumor suppressor gene PTPRJ in early-onset familial colorectal cancer. Gastroenterology 2010;139:2221-2224.

7. Petermann A, Haase D, Wetzel A, Balavenkatraman KK, Tenev T, Guhrs KH, et al. Loss of the -tyrosine phosphatase DEP-1/PTPRJ drives meningioma cell motility. Brain Pathol 2011;21:405-418.

8. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, et al. The mechanism of growth-inhibitory effect of DOC- 2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC- 2/DAB2. J Biol Chem 2002;277:12622-12631.

9. Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H, et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res 2004;10:2082-2089.

10. Yano M, Toyooka S, Tsukuda K, Dote H, Ouchida M, Hanabata T, et al. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer 2005;113:59-66.

11. Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, Liu J, et al. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget 2010;1:265-277.

12. Matsui S, Utani A, Takahashi K, Mukoyama Y, Miyachi Y, Matsuyoshi N. Knockdown of Fat2 by siRNA inhibits the migration of human squamous carcinoma cells. J Dermatol Sci 2008;51:207-210.

13. Whitmore SA, Settasatian C, Crawford J, Lower KM, McCallum B, Seshadri R, et al. Characterization and screening for mutations of the growth arrest-specific 11 (GAS11) and C16orf3 genes at 16q24.3 in breast cancer. Genomics 1998;52:325- 331.

14. Liu CX, Musco S, Lisitsina NM, Yaklichkin SY, Lisitsyn NA. Genomic organization of a new candidate tumor suppressor gene, LRP1B. Genomics 2000;69:271-274.

15. Langbein S, Szakacs O, Wilhelm M, Sukosd F, Weber S, Jauch A, et al. Alteration of the LRP1B gene region is associated with high grade of urothelial cancer. Lab Invest 2002;82:639-643.

16. Prazeres H, Torres J, Rodrigues F, Pinto M, Pastoriza MC, Gomes D, et al. Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene 2011;30:1302-1317.

17. Kim M, Kim JH, Jang HR, Kim HM, Lee CW, Noh SM, et al. LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer. Cancer Res 2008;68:7147-7155.

18. Tian XQ, Zhang Y, Sun D, Zhao S, Xiong H, Fang J. Epigenetic silencing of LRRC3B in colorectal cancer. Scand J Gastroenterol 2009;44:79-84. 19. Efimova E, Martinez O, Lokshin A, Arima T, Prabhakar BS. IG20, a MADD splice variant, increases cell susceptibility to gamma- irradiation and induces soluble mediators that suppress tumor cell growth. Cancer Res 2003;63:8768-8776.

20. Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 1998;101:153-159.

21. Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology 2006;131:797-808.

22. Ostrow KL, Park HL, Hoque MO, Kim MS, Liu J, Argani P, et al. Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res 2009;15:1184-1191.

23. Bennett KL, Karpenko M, Lin MT, Claus R, Arab K, Dyckhoff G, et al. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res 2008;68:4494-4499.

24. Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 2009;101:916-927.

25. Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, et al. OPCML at 11q25 is epigenetically inactivated and has tumor- suppressor function in epithelial ovarian cancer. Nat Genet 2003;34:337-343.

26. Reed JE, Dunn JR, du Plessis DG, Shaw EJ, Reeves P, Gee AL, et al. Expression of cellular adhesion molecule 'OPCML' is down- regulated in gliomas and other brain tumours. Neuropathol Appl Neurobiol 2007;33:77-85.

27. Di MA, Viganotti M, Antoccia A, Magrelli A, Salvatore M, Azzalin G, et al. Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/beta - catenin pathway, microRNA expression and protein expression profile. Cell Mol Biol (Noisy -le-grand) 2010;56 Suppl:OL1299-OL1317.

28. Zheng JF, Sun LC, Liu H, Huang Y, Li Y, He J. EBP50 exerts tumor suppressor activity by promoting cell apoptosis and retarding extracellular signal-regulated kinase activity. Amino Acids 2010;38:1261-1268.

29. Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res 2005;65:4598-4606.

30. Dong W, Chen X, Xie J, Sun P, Wu Y. Epigenetic inactivation and tumor suppressor activity of HAI-2/SPINT2 in gastric cancer. Int J Cancer 2010;127:1526-1534.

31. Kongkham PN, Northcott PA, Ra YS, Nakahara Y, Mainprize TG, Croul SE, et al. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res 2008;68:9945-9953.

32. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998;58:2196- 2199.

33. Yuan BZ, Zhou X, Durkin ME, Zimonjic DB, Gumundsdottir K, Eyfjord JE, et al. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene 2003;22:445-450.

34. Pang JC, Chang Q, Chung YF, Teo JG, Poon WS, Zhou LF, et al. Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor. Hum Pathol 2005;36:36-43.

35. Kresse SH, Ohnstad HO, Paulsen EB, Bjerkehagen B, Szuhai K, Serra M, et al. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. Genes Cancer 2009;48:679- 693.

36. Zeller C, Hinzmann B, Seitz S, Prokoph H, Burkhard-Goettges E, Fischer J, et al. SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer. Oncogene 2003;22:2972-2983. 37. Rimkus C, Martini M, Friederichs J, Rosenberg R, Doll D, Siewert JR, et al. Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer 2006;95:1419-1423.

38. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon DS. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res 2004;10:7475-7483.

39. Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 2005;37:265-274.

40. Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, et al. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 2008;8:154.

41. Carey JP, Asirvatham AJ, Galm O, Ghogomu TA, Chaudhary J. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer. BMC Cancer 2009;9:173.

42. Huynh HT, Larsson C, Narod S, Pollak M. Tumor suppressor activity of the gene encoding mammary-derived growth inhibitor. Cancer Res 1995;55:2225-2231.

43. Gruber AD, Pauli BU. Tumorigenicity of human breast cancer is associated with loss of the Ca2+-activated CLCA2. Cancer Res 1999;59:5488-5491.

44. Bustin SA, Li SR, Dorudi S. Expression of the Ca2+-activated chloride channel genes CLCA1 and CLCA2 is downregulated in human colorectal cancer. DNA Cell Biol 2001;20:331-338.

45. Yu JH, Zhu BM, Wickre M, Riedlinger G, Chen W, Hosui A, et al. The transcription factors signal transducer and activator of transcription 5A (STAT5A) and STAT5B negatively regulate cell proliferation through the activation of cyclin-dependent kinase inhibitor 2b (Cdkn2b) and Cdkn1a expression. Hepatology 2010;52:1808-1818.

46. Silva FP, Morolli B, Storlazzi CT, Anelli L, Wessels H, Bezrookove V, et al. Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene 2003;22:538-547.

47. Berx G, Becker KF, Hofler H, van RF. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998;12:226-237.

48. Efstathiou JA, Liu D, Wheeler JM, Kim HC, Beck NE, Ilyas M, et al. Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci U S A 1999;96:2316-2321.

49. Dhillon VS, Young AR, Husain SA, Aslam M. Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin. Br J Cancer 2004;90:874-881.

50. Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, Timmons CF, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002;21:4345-4349.